Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""everolimus"" wg kryterium: Temat


Tytuł :
Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.
Autorzy :
Hatano T; Department of Urology, JR Tokyo General Hospital, Japan. Electronic address: .
Egawa S; Department of Urology, Jikei University School of Medicine, Japan.
Pokaż więcej
Źródło :
Asian journal of surgery [Asian J Surg] 2020 Oct; Vol. 43 (10), pp. 967-972. Date of Electronic Publication: 2020 Jan 17.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Angiomyolipoma/*therapy
Embolization, Therapeutic/*methods
Everolimus/*therapeutic use
Kidney Neoplasms/*therapy
Nephrectomy/*methods
TOR Serine-Threonine Kinases/*antagonists & inhibitors
Tuberous Sclerosis/*complications
Age Factors ; Algorithms ; Angiomyolipoma/classification ; Angiomyolipoma/complications ; Angiomyolipoma/pathology ; Everolimus/pharmacology ; Hemorrhage/etiology ; Humans ; Kidney Neoplasms/classification ; Kidney Neoplasms/pathology ; Minimally Invasive Surgical Procedures/methods ; Retroperitoneal Space ; Rupture, Spontaneous
Czasopismo naukowe
Tytuł :
Durable polymer everolimus-eluting stents: history, current status and future prospects.
Autorzy :
Rodríguez-Arias JJ; Clinic Cardiovascular Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona , Barcelona, Spain.
Ortega-Paz L; Clinic Cardiovascular Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona , Barcelona, Spain.
Brugaletta S; Clinic Cardiovascular Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona , Barcelona, Spain.
Pokaż więcej
Źródło :
Expert review of medical devices [Expert Rev Med Devices] 2020 Jul; Vol. 17 (7), pp. 671-682. Date of Electronic Publication: 2020 Jun 30.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug-Eluting Stents/*trends
Everolimus/*therapeutic use
Polymers/*chemistry
Acute Coronary Syndrome/drug therapy ; Drug-Eluting Stents/adverse effects ; Everolimus/adverse effects ; Everolimus/chemistry ; Humans ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Very late-phase vascular response after everolimus-eluting stent implantation assessed by optical coherence tomography.
Autorzy :
Khalifa AKM; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Ino Y; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan. .
Kubo T; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Tanimoto T; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Shimamura K; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Shiono Y; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Takahata M; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Terada K; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Higashioka D; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Wada T; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Taruya A; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Emori H; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Katayama Y; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Kashiwagi M; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Kuroi A; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Matsuo Y; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Fujita S; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Tanaka A; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Hozumi T; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Akasaka T; Department of Cardiovascular Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Pokaż więcej
Źródło :
The international journal of cardiovascular imaging [Int J Cardiovasc Imaging] 2020 Sep; Vol. 36 (9), pp. 1627-1635. Date of Electronic Publication: 2020 May 08.
Typ publikacji :
Journal Article
MeSH Terms :
Drug-Eluting Stents*
Tomography, Optical Coherence*
Cardiovascular Agents/*administration & dosage
Coronary Artery Disease/*therapy
Coronary Vessels/*diagnostic imaging
Everolimus/*administration & dosage
Percutaneous Coronary Intervention/*instrumentation
Aged ; Aged, 80 and over ; Atherectomy, Coronary ; Cardiovascular Agents/adverse effects ; Coronary Artery Disease/diagnostic imaging ; Everolimus/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Percutaneous Coronary Intervention/adverse effects ; Predictive Value of Tests ; Prosthesis Design ; Registries ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation.
Autorzy :
Camporese G; Angiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, Padova University Hospital, Italy. Electronic address: .
Bernardi D; Department of Laboratory Medicine, Padova University Hospital, Italy.
Bernardi E; Department of Emergency and Accident Medicine, Conegliano Hospital, Italy.
Avruscio GP; Angiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, Padova University Hospital, Italy.
Marchini F; Division of Nephrology and Renal Transplantation, Padova University Hospital, Italy.
Bonfante L; Division of Nephrology and Renal Transplantation, Padova University Hospital, Italy.
Furian L; Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Italy.
Neri F; Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Italy.
Villalta S; Department of Internal Medicine, Internal Medicine AULSS2 Marca Trevigiana, Treviso Hospital, Italy.
Fabris F; Department of Internal Medicine, Clinical Medicine 1, Padova University Hospital, Italy.
Simioni P; Department of Internal Medicine, General Medicine Unit, Thrombotic and Haemorrhagic Disorders Unit, Padova University Hospital, Italy.
Sartori MT; Department of Internal Medicine, Clinical Medicine 1, Padova University Hospital, Italy.
Pokaż więcej
Źródło :
Vascular pharmacology [Vascul Pharmacol] 2020 Jul; Vol. 130, pp. 106682. Date of Electronic Publication: 2020 May 11.
Typ publikacji :
Journal Article
MeSH Terms :
Kidney Transplantation*/adverse effects
Atrial Fibrillation/*drug therapy
Everolimus/*pharmacokinetics
Factor Xa Inhibitors/*pharmacokinetics
Immunosuppressive Agents/*pharmacokinetics
Rivaroxaban/*pharmacokinetics
Tacrolimus/*pharmacokinetics
Venous Thrombosis/*drug therapy
Aged ; Atrial Fibrillation/blood ; Atrial Fibrillation/diagnosis ; Blood Coagulation/drug effects ; Drug Interactions ; Drug Monitoring ; Everolimus/adverse effects ; Everolimus/blood ; Factor Xa Inhibitors/adverse effects ; Factor Xa Inhibitors/blood ; Female ; Graft Survival/drug effects ; Hemorrhage/chemically induced ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/blood ; Male ; Middle Aged ; Pilot Projects ; Prospective Studies ; Rivaroxaban/adverse effects ; Rivaroxaban/blood ; Tacrolimus/adverse effects ; Tacrolimus/blood ; Treatment Outcome ; Venous Thrombosis/blood ; Venous Thrombosis/diagnosis
Czasopismo naukowe
Tytuł :
Chronic stent recoil in severely calcified coronary artery lesions. A serial optical coherence tomography study.
Autorzy :
Amemiya K; Showa University Northern Yokohama Hospital, Yokohama, Japan.
Maehara A; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA. .; NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY, USA. .
Yamamoto MH; Showa University Northern Yokohama Hospital, Yokohama, Japan.
Oyama Y; Showa University Northern Yokohama Hospital, Yokohama, Japan.
Igawa W; Showa University Northern Yokohama Hospital, Yokohama, Japan.
Ono M; Showa University Northern Yokohama Hospital, Yokohama, Japan.
Kido T; Showa University Northern Yokohama Hospital, Yokohama, Japan.
Ebara S; Showa University Northern Yokohama Hospital, Yokohama, Japan.
Okabe T; Showa University Northern Yokohama Hospital, Yokohama, Japan.
Yamashita K; Showa University Northern Yokohama Hospital, Yokohama, Japan.
Isomura N; Showa University Northern Yokohama Hospital, Yokohama, Japan.
Mintz GS; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA.
Ochiai M; Showa University Northern Yokohama Hospital, Yokohama, Japan.
Pokaż więcej
Źródło :
The international journal of cardiovascular imaging [Int J Cardiovasc Imaging] 2020 Sep; Vol. 36 (9), pp. 1617-1626. Date of Electronic Publication: 2020 May 27.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Drug-Eluting Stents*
Tomography, Optical Coherence*
Cardiovascular Agents/*administration & dosage
Coronary Artery Disease/*therapy
Coronary Vessels/*diagnostic imaging
Everolimus/*administration & dosage
Percutaneous Coronary Intervention/*instrumentation
Vascular Calcification/*therapy
Aged ; Atherectomy, Coronary ; Cardiovascular Agents/adverse effects ; Chronic Disease ; Coronary Artery Disease/diagnostic imaging ; Everolimus/adverse effects ; Female ; Humans ; Male ; Neointima ; Percutaneous Coronary Intervention/adverse effects ; Predictive Value of Tests ; Prospective Studies ; Prosthesis Design ; Severity of Illness Index ; Time Factors ; Treatment Outcome ; Vascular Calcification/diagnostic imaging
Czasopismo naukowe
Tytuł :
Early and Midterm Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Asian Patients With Chronic Limb-Threatening Ischemia: One-Year Clinical and Imaging Outcomes From the DISAPEAR Registry.
Autorzy :
Kum S; Vascular Service, Department of Surgery, Changi General Hospital, Singapore.
Ipema J; Department of Vascular Surgery, Northwest Clinics, Alkmaar, the Netherlands.
Chun-Yin DH; Vascular Service, Department of Surgery, Changi General Hospital, Singapore.
Lim DM; Vascular Service, Department of Surgery, Changi General Hospital, Singapore.
Tan YK; Vascular Service, Department of Surgery, Changi General Hospital, Singapore.
Varcoe RL; Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.; Department of Surgery, Prince of Wales Hospital, Sydney, New South Wales, Australia.; The Vascular Institute, Prince of Wales Hospital, Sydney, New South Wales, Australia.
Hazenberg CEVB; Department of Vascular Surgery, University Medical Center Utrecht, the Netherlands.
Ünlü Ç; Department of Vascular Surgery, Northwest Clinics, Alkmaar, the Netherlands.
Pokaż więcej
Źródło :
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists [J Endovasc Ther] 2020 Aug; Vol. 27 (4), pp. 616-622. Date of Electronic Publication: 2020 May 29.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Absorbable Implants*
Popliteal Artery*/diagnostic imaging
Popliteal Artery*/physiopathology
Cardiovascular Agents/*administration & dosage
Endovascular Procedures/*instrumentation
Everolimus/*administration & dosage
Ischemia/*therapy
Peripheral Arterial Disease/*therapy
Aged ; Amputation ; Asian Continental Ancestry Group ; Cardiovascular Agents/adverse effects ; Chronic Disease ; Endovascular Procedures/adverse effects ; Everolimus/adverse effects ; Female ; Humans ; Ischemia/diagnostic imaging ; Ischemia/ethnology ; Limb Salvage ; Male ; Middle Aged ; Peripheral Arterial Disease/diagnostic imaging ; Peripheral Arterial Disease/ethnology ; Prosthesis Design ; Registries ; Retrospective Studies ; Risk Factors ; Singapore ; Time Factors ; Treatment Outcome ; Vascular Patency ; Wound Healing
Czasopismo naukowe
Tytuł :
Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.
Autorzy :
Meziyerh S; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
Zwart TC; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
van Etten RW; Department of Internal Medicine, Division of Nephrology, Amphia Hospital, Breda, The Netherlands.
Janson JA; Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands.
van Gelder T; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Alwayn IPJ; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.; Department of Surgery, Division of Transplantation Surgery, Leiden University Medical Center, Leiden, The Netherlands.
de Fijter JW; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
Reinders MEJ; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
Moes DJAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
de Vries APJ; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
Pokaż więcej
Źródło :
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2020 Jul; Vol. 20 (7), pp. 1896-1901. Date of Electronic Publication: 2020 May 13.
Typ publikacji :
Case Reports
MeSH Terms :
Kidney Transplantation*
Transplant Recipients*
Coronavirus Infections/*complications
Coronavirus Infections/*therapy
Everolimus/*pharmacokinetics
Kidney Failure, Chronic/*complications
Pneumonia, Viral/*complications
Pneumonia, Viral/*therapy
Adult ; Antiviral Agents/administration & dosage ; Antiviral Agents/pharmacokinetics ; Betacoronavirus ; Chloroquine/administration & dosage ; Chloroquine/pharmacokinetics ; Drug Combinations ; Drug Interactions ; Everolimus/administration & dosage ; Humans ; Immunocompromised Host ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/pharmacokinetics ; Kidney Failure, Chronic/surgery ; Lopinavir/administration & dosage ; Lopinavir/pharmacokinetics ; Male ; Netherlands ; Pandemics ; Radiography, Thoracic ; Ritonavir/administration & dosage ; Ritonavir/pharmacokinetics ; Treatment Outcome
SCR Disease Name :
COVID-19
Raport
Tytuł :
The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose ( F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors.
Autorzy :
Lung MS; Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Hicks RJ; Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
Pavlakis N; Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, NSW, Australia.
Link E; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.; Biostatistics and Clinical Trials Centre, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre Building, Melbourne, VIC, Australia.
Jefford M; Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
Thomson B; Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; University of Melbourne Department of Surgery, Royal Melbourne Hospital, Parkville, VIC, Australia.
Wyld DK; Department of Medical Oncology, Royal Brisbane and Women's Hospital, QLD, Australia.; School of Medicine, University of Queensland, QLD, Australia.
Liauw W; Department of Medical Oncology, Cancer Care Centre, Kogarah, NSW, Australia.
Akhurst T; Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
Kuru N; Biostatistics and Clinical Trials Centre, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre Building, Melbourne, VIC, Australia.
Michael M; Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
Pokaż więcej
Źródło :
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2020 Jun; Vol. 16 (3), pp. 150-157. Date of Electronic Publication: 2020 Feb 07.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Everolimus/*therapeutic use
Fluorodeoxyglucose F18/*therapeutic use
Neuroendocrine Tumors/*diagnostic imaging
Pancreatic Neoplasms/*diagnostic imaging
Positron-Emission Tomography/*methods
Radiopharmaceuticals/*therapeutic use
Adult ; Aged ; Everolimus/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Neuroendocrine Tumors/mortality ; Neuroendocrine Tumors/pathology ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Survival Rate
Czasopismo naukowe
Tytuł :
Coronary vasomotor function and myocardial flow with bioresorbable vascular scaffolds or everolimus-eluting metallic stents: a randomised trial.
Autorzy :
Gomez-Lara J; Grup de Recerca en Malalties del Cor, Hospital Universitari de Bellvitge; Institut d´Investigacio Biomedica de Bellvitge (IDIBELL), Universitat de Barcelona, L´Hospitalet de Llobregat, Spain.
Salvatella N
Romaguera R
Brugaletta S
Ñato M
Roura G
Ferreiro JL
Teruel L
Gracida M
Sabate M
Vaquerizo B
Cequier À
Gomez-Hospital JA
Pokaż więcej
Corporate Authors :
Collaborators
Źródło :
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology [EuroIntervention] 2020 Jun 12; Vol. 16 (2), pp. e155-e163. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Absorbable Implants*
Drug-Eluting Stents*
Percutaneous Coronary Intervention*
Tissue Scaffolds*
Everolimus/*administration & dosage
Hyperemia/*diagnostic imaging
Microcirculation/*drug effects
Coronary Angiography ; Everolimus/therapeutic use ; Humans ; Hyperemia/therapy ; Prosthesis Design ; Treatment Outcome ; Ultrasonography, Doppler
Czasopismo naukowe
Tytuł :
Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial.
Autorzy :
Takahashi K; Department of Cardiology, Amsterdam Universities Medical Centers, Location Academic Medical Center, University of Amsterdam, the Netherlands. (K.T., N.K., K.T.K., J.J.W., R.J.d.W.).
Serruys PW; Department of Cardiology, National University of Ireland, Galway (NUIG) (P.W.S., Y.O.).
Kogame N; Department of Cardiology, Amsterdam Universities Medical Centers, Location Academic Medical Center, University of Amsterdam, the Netherlands. (K.T., N.K., K.T.K., J.J.W., R.J.d.W.).
Buszman P; Department of Epidemiology and Statistics, Medical University of Silesia, Katowice, Poland (P.B.).; Centre for Cardiovascular Research and Development, American Heart of Poland, Ustron (P.B., K.P.M.).
Lurz P; Department of Internal Medicine/Cardiology, Heart Center Leipzig at University Leipzig, Germany (P.L.).
Jessurun GAJ; Department of Cardiology, Treant Zorggroep, Emmen, the Netherlands (G.A.J.J.).
Koch KT; Department of Cardiology, Amsterdam Universities Medical Centers, Location Academic Medical Center, University of Amsterdam, the Netherlands. (K.T., N.K., K.T.K., J.J.W., R.J.d.W.).
Troquay RPT; Department of Cardiology, VieCuri Medical Centre for Northern Limburg, Venlo, the Netherlands (R.P.T.T.).
Hamer BJB; Department of Cardiology, Meander Medisch Centrum, Amersfoort, the Netherlands (B.J.B.H.).
Oude Ophuis T; Department of Cardiology, Canisius Wilhelmina Ziekenhuis, Nijmegen, the Netherlands (T.O.O.).
Milewski KP; Centre for Cardiovascular Research and Development, American Heart of Poland, Ustron (P.B., K.P.M.).
Hofma SH; Department of Cardiology, Medisch Centrum Leeuwarden, the Netherlands (S.H.H.).
Wykrzykowska JJ; Department of Cardiology, Amsterdam Universities Medical Centers, Location Academic Medical Center, University of Amsterdam, the Netherlands. (K.T., N.K., K.T.K., J.J.W., R.J.d.W.).
Onuma Y; Department of Cardiology, National University of Ireland, Galway (NUIG) (P.W.S., Y.O.).
de Winter RJ; Department of Cardiology, Amsterdam Universities Medical Centers, Location Academic Medical Center, University of Amsterdam, the Netherlands. (K.T., N.K., K.T.K., J.J.W., R.J.d.W.).
Wijns W; The Lambe Institute for Translational Medicine and Curam, National University of Ireland Galway (W.W.).
Pokaż więcej
Źródło :
Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2020 Jun; Vol. 13 (6), pp. e008737. Date of Electronic Publication: 2020 May 29.
Typ publikacji :
Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Absorbable Implants*
Drug-Eluting Stents*
Cardiovascular Agents/*administration & dosage
Everolimus/*administration & dosage
Myocardial Ischemia/*therapy
Percutaneous Coronary Intervention/*instrumentation
Polymers/*chemistry
Aged ; Cardiovascular Agents/adverse effects ; Europe ; Everolimus/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Myocardial Ischemia/mortality ; Percutaneous Coronary Intervention/adverse effects ; Percutaneous Coronary Intervention/mortality ; Prospective Studies ; Prosthesis Design ; Risk Factors ; Single-Blind Method ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus.
Autorzy :
Li T; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Xu XH; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Guo X; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Yuan T; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Tang ZH; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Jiang XM; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Xu YL; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Zhang LL; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Chen X; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Zhu H; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Shi JJ; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Lu JJ; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China. Electronic address: .
Pokaż więcej
Źródło :
Biochemical pharmacology [Biochem Pharmacol] 2020 May; Vol. 175, pp. 113921. Date of Electronic Publication: 2020 Mar 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA-Binding Proteins/*metabolism
Everolimus/*pharmacology
Lung Neoplasms/*metabolism
Receptor, Notch3/*metabolism
TOR Serine-Threonine Kinases/*metabolism
Transcription Factor CHOP/*metabolism
Transcription Factors/*metabolism
A549 Cells ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Apoptosis/drug effects ; Apoptosis/physiology ; Cell Line, Tumor ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/physiology ; Everolimus/therapeutic use ; HEK293 Cells ; Humans ; Lung Neoplasms/drug therapy ; TOR Serine-Threonine Kinases/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies.
Autorzy :
Sorrentino S; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Claessen BE; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Chandiramani R; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Guedeney P; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Vogel B; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Baber U; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Rau V; Abbott Vascular, Santa Clara, CA (V.R., J.W.).
Wang J; Abbott Vascular, Santa Clara, CA (V.R., J.W.).
Krucoff M; Duke University Medical Center, Durham, NC (M.K.).
Kozuma K; Teikyo University, Tokyo, Japan (K.K.).
Ge J; Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China (J.G.).
Seth A; Fortis Escorts Heart Institute, New Delhi, India (A.S.).
Makkar R; Cedars-Sinai Medical Center, Los Angeles, CA (R. Makkar).
Liu Y; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Bangalore S; New York University Langone Medical Center (S.B.).
Bhatt DL; Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.).
Angiolillo DJ; University of Florida College of Medicine-Jacksonville (D.J.A.).
Saito S; Shonan Kamakura General Hospital, Japan (S.S.).
Neumann FJ; University of Freiburg, Germany (F.-J.N.).
Hermiller J; St Vincent's Medical Center of Indiana, Indianapolis (J.H.).
Valgimigli M; Bern University Hospital, Switzerland (M.V.).
Mehran R; Mount Sinai Medical Center, New York (S.S., B.E.C., R.C., P.G., B.V., U.B., Y.L., R. Mehran).
Pokaż więcej
Źródło :
Circulation [Circulation] 2020 Mar 17; Vol. 141 (11), pp. 891-901. Date of Electronic Publication: 2020 Jan 29.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Coronary Stenosis/*therapy
Coronary Thrombosis/*etiology
Drug-Eluting Stents/*adverse effects
Everolimus/*adverse effects
Hemorrhage/*etiology
Myocardial Infarction/*etiology
Percutaneous Coronary Intervention/*instrumentation
Aged ; Aged, 80 and over ; Cause of Death ; Chromium ; Cobalt ; Comorbidity ; Coronary Restenosis/epidemiology ; Coronary Restenosis/etiology ; Coronary Stenosis/complications ; Coronary Thrombosis/epidemiology ; Drug Therapy, Combination ; Everolimus/administration & dosage ; Everolimus/therapeutic use ; Female ; Hemorrhage/epidemiology ; Hemorrhagic Disorders/epidemiology ; Humans ; Kaplan-Meier Estimate ; Male ; Metabolic Syndrome/epidemiology ; Middle Aged ; Mortality ; Myocardial Infarction/epidemiology ; Platelet Aggregation Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/therapeutic use ; Polymers ; Prevalence ; Proportional Hazards Models ; Prospective Studies ; Registries ; Smoking/epidemiology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Autorzy :
Donskov F; Aarhus University Hospital, Aarhus, Denmark. Electronic address: .
Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Voog E; Centre Jean Bernard Clinique Victor Hugo, Le Mans, France.
Hovey E; Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Randwick, Australia.
Grüllich C; National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.
Nott LM; Royal Hobart Hospital, Hobart, Australia.
Cuff K; Princess Alexandra Hospital, Woolloongabba, Australia.
Gil T; Institute Jules Bordet, Brussels, Belgium.
Jensen NV; Odense Universitetshospital, Odense, Denmark.
Chevreau C; Institut Universitaire Du Cancer Toulouse, Toulouse, France.
Negrier S; Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France.
Depenbusch R; Onkologische Schwerpunktpraxis Gütersloh, Gütersloh, Germany.
Bergmann L; Universitätsklinik Frankfurt Hospital, Frankfurt, Germany.
Cornelio I; Exelixis, Alameda, CA, USA.
Champsaur A; Exelixis, Alameda, CA, USA.
Escudier B; Gustave Roussy, Villejuif, France.
Pal S; City of Hope National Medical Center, Duarte, CA, USA.
Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK.
Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA.
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Feb; Vol. 126, pp. 1-10. Date of Electronic Publication: 2019 Dec 27.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Anilides/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Everolimus/*therapeutic use
Kidney Neoplasms/*drug therapy
Outcome Assessment, Health Care/*methods
Pyridines/*therapeutic use
Adult ; Age Factors ; Aged ; Anilides/adverse effects ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Diarrhea/chemically induced ; Everolimus/adverse effects ; Fatigue/chemically induced ; Female ; Humans ; Hypertension/chemically induced ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Outcome Assessment, Health Care/statistics & numerical data ; Proportional Hazards Models ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Pyridines/adverse effects ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity.
Autorzy :
Houdaihed L; Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
Evans JC; Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
Allen C; Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. .
Pokaż więcej
Źródło :
Pharmaceutical research [Pharm Res] 2020 Jan 21; Vol. 37 (3), pp. 39. Date of Electronic Publication: 2020 Jan 21.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*chemistry
Breast Neoplasms/*drug therapy
Everolimus/*chemistry
Nanocapsules/*chemistry
Paclitaxel/*chemistry
Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/chemistry ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Cell Line, Tumor ; Cell Survival ; Drug Compounding/methods ; Drug Liberation ; ErbB Receptors/metabolism ; Everolimus/pharmacology ; Female ; Humans ; Molecular Targeted Therapy/methods ; Paclitaxel/pharmacology ; Panitumumab/chemistry ; Panitumumab/metabolism ; Polylactic Acid-Polyglycolic Acid Copolymer/chemistry ; Receptor, ErbB-2/metabolism ; Surface Properties ; Trastuzumab/chemistry ; Trastuzumab/metabolism
Czasopismo naukowe
Tytuł :
Randomized Comparison of Everolimus- and Zotarolimus-Eluting Coronary Stents With Biolimus-Eluting Stents in All-Comer Patients.
Autorzy :
Youn YJ; Division of Cardiology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, South Korea (Y.J.Y., J.-W.L., S.G.A., S.-H.L., J.Y.).
Lee JW; Division of Cardiology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, South Korea (Y.J.Y., J.-W.L., S.G.A., S.-H.L., J.Y.).
Ahn SG; Division of Cardiology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, South Korea (Y.J.Y., J.-W.L., S.G.A., S.-H.L., J.Y.).
Lee SH; Division of Cardiology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, South Korea (Y.J.Y., J.-W.L., S.G.A., S.-H.L., J.Y.).
Yoon J; Division of Cardiology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, South Korea (Y.J.Y., J.-W.L., S.G.A., S.-H.L., J.Y.).
Park KS; Division of Cardiology, Inha University Hospital, Inha University College of Medicine, Incheon, South Korea (K.S.P.).
Lee JB; Division of Cardiology, Daegu Catholic University Medical Center, Catholic University, South Korea (J.-B.L.).
Yoo SY; Division of Cardiology, Gangneung Asan Hospital, University of Ulsan College of Medicine, South Korea (S.-Y.Y.).
Lim DS; Division of Cardiology, Korea University Anam Hospital (D.-S.L.), Korea University, Seoul, South Korea.
Cho JH; Division of Cardiology, St. Carollo General Hospital, Suncheon, South Korea (J.H.C.).
Choi CU; Division of Cardiology, Korea University Guro Hospital (C.U.C.), Korea University, Seoul, South Korea.
Jeong MH; The Heart Center, Chonnam National University Hospital, Chonnam National University, Gwangju, South Korea (M.H.J.).
Han KR; Division of Cardiology, Kangdong Sacred Heart Hospital Hallym University, Seoul (K.-R.H.).
Cha KS; Division of Cardiology, Pusan National University Hospital, Pusan National University, Busan, South Korea (K.S.C.).
Lee SY; Division of Cardiology, Inje University Ilsan-Paik Hospital, Inje University, Goyang, South Korea (S.Y.L.).
Choi HH; Division of Cardiology, Chuncheon Sacred Heart Hospital, Hallym University, South Korea (H.-H.C.).
Choi JW; Division of Cardiology, Eulji General Hospital, Eulji University, Seoul, South Korea (J.W.C.).
Hyon MS; Division of Cardiology, Soonchunhyang University Seoul Hospital, Soonchunhyang University, South Korea (M.S.H.).
Kim MH; Division of Cardiology, Dong-A University Hospital, Dong-A University, Busan, South Korea (M.-H.K.).
Pokaż więcej
Źródło :
Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2020 Mar; Vol. 13 (3), pp. e008525. Date of Electronic Publication: 2020 Mar 12.
Typ publikacji :
Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug-Eluting Stents*
Cardiovascular Agents/*administration & dosage
Everolimus/*administration & dosage
Myocardial Ischemia/*therapy
Percutaneous Coronary Intervention/*instrumentation
Sirolimus/*analogs & derivatives
Aged ; Cardiovascular Agents/adverse effects ; Early Termination of Clinical Trials ; Everolimus/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Myocardial Ischemia/mortality ; Percutaneous Coronary Intervention/adverse effects ; Percutaneous Coronary Intervention/mortality ; Prosthesis Design ; Recurrence ; Republic of Korea ; Risk Factors ; Sirolimus/administration & dosage ; Sirolimus/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex.
Autorzy :
Krymskaya VP; Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA.
Courtwright AM; Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA.
Fleck V; Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA.
Dorgan D; Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA.
Kotloff R; Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, USA.
McCormack FX; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Kreider M; Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, Philadelphia, PA, USA. Electronic address: .
Pokaż więcej
Źródło :
Respiratory medicine [Respir Med] 2020 Mar; Vol. 163, pp. 105898. Date of Electronic Publication: 2020 Feb 08.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Everolimus/*adverse effects
Lymphangioleiomyomatosis/*drug therapy
Simvastatin/*adverse effects
Tuberous Sclerosis/*drug therapy
Drug Therapy, Combination ; Everolimus/administration & dosage ; Female ; Forced Expiratory Volume ; Humans ; Lymphangioleiomyomatosis/complications ; Lymphangioleiomyomatosis/physiopathology ; Male ; Safety ; Simvastatin/administration & dosage ; Sirolimus/administration & dosage ; Treatment Outcome ; Tuberous Sclerosis/complications ; Tuberous Sclerosis/physiopathology
Czasopismo naukowe
Tytuł :
Very Late Scaffold Thrombosis after Everolimus-Eluting Bioresorbable Scaffold Implantation in Patients with Unremarkable Interim Surveillance Angiography.
Autorzy :
Hoppmann P; Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technische Universität München, Germany.
Rai H; Deutsches Herzzentrum München, Technische Universität München, Germany.
Colleran R; Deutsches Herzzentrum München, Technische Universität München, Germany.
Kufner S; Deutsches Herzzentrum München, Technische Universität München, Germany.
Wiebe J; Deutsches Herzzentrum München, Technische Universität München, Germany.
Cassese S; Deutsches Herzzentrum München, Technische Universität München, Germany.
Joner M; Deutsches Herzzentrum München, Technische Universität München, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany.
Laugwitz KL; Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technische Universität München, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany.
Kastrati A; Deutsches Herzzentrum München, Technische Universität München, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany.
Byrne RA; Deutsches Herzzentrum München, Technische Universität München, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Germany. Electronic address: .
Pokaż więcej
Źródło :
Cardiovascular revascularization medicine : including molecular interventions [Cardiovasc Revasc Med] 2020 Mar; Vol. 21 (3), pp. 361-366. Date of Electronic Publication: 2019 May 30.
Typ publikacji :
Case Reports; Journal Article; Multicenter Study
MeSH Terms :
Absorbable Implants*
Coronary Angiography*
Tomography, Optical Coherence*
Cardiovascular Agents/*administration & dosage
Coronary Artery Disease/*diagnostic imaging
Coronary Thrombosis/*diagnostic imaging
Everolimus/*administration & dosage
Percutaneous Coronary Intervention/*instrumentation
Aged ; Cardiovascular Agents/adverse effects ; Coronary Artery Disease/therapy ; Coronary Thrombosis/etiology ; Dual Anti-Platelet Therapy ; Everolimus/adverse effects ; Female ; Germany ; Humans ; Male ; Middle Aged ; Percutaneous Coronary Intervention/adverse effects ; Platelet Aggregation Inhibitors/administration & dosage ; Predictive Value of Tests ; Prosthesis Design ; Risk Factors ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
Autorzy :
Kim D; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Koh Y; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea .; Center for Medical Innovation, Seoul National University Hospital, Seoul, Republic of Korea.; Center for Precision Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Yoon SS; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea .; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Mar; Vol. 40 (3), pp. 1395-1403.
Typ publikacji :
Journal Article
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Carbazoles/*pharmacology
Everolimus/*pharmacology
Lymphoma, Large-Cell, Anaplastic/*drug therapy
Lymphoma, Large-Cell, Anaplastic/*enzymology
Piperidines/*pharmacology
Anaplastic Lymphoma Kinase/biosynthesis ; Carbazoles/administration & dosage ; Cell Cycle Checkpoints/drug effects ; Cell Growth Processes/drug effects ; Cell Line, Tumor ; Crizotinib/administration & dosage ; Crizotinib/pharmacology ; Drug Synergism ; Everolimus/administration & dosage ; Humans ; Jurkat Cells ; Lymphoma, Large-Cell, Anaplastic/pathology ; Piperidines/administration & dosage ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies